GlassScriptPhysician profile
Debra J Hoffman
NPI 1750575494
$1,994.80
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $274 · 2023: $930 · 2024: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.11 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $289.07 | 2023-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.80 | 2023-2024 | Caplyta |
| Abbvie INC. | $204.61 | 2021-2023 | |
| Novo Nordisk INC | $200.29 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $153.24 | 2022-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $139.70 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $124.13 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $112.68 | 2023-2024 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $66.95 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $64.19 | 2022-2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $59.75 | 2023-2024 | Quviviq |
| Pfizer INC. | $50.38 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $43.58 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.38 | 2024 | |
| Abbott Laboratories | $35.42 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $33.44 | 2023-2024 | Unithroid |
| Merck Sharp & Dohme LLC | $28.61 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sumitomo Pharma America, INC. | $22.63 | 2024 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $21.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.